

PORTER WRIGHT MORRIS & ARTHUR_{LLP}
Attorneys & Counselors at Law

Richard M. Mescher
614-227-2026

41 South High Street
Columbus, Ohio 43215-6194

Facsimile: 614-227-2100
Toll Free: 800-533-2794

September 6, 2001

VIA EXPRESS MAIL RECEIPT NO. EL 817538189US

Box PCT
Commissioner for Patents
Washington, D.C. 20231

Re: First Inventor: James Allen
Int'l App. No.: PCT/IB00/00205
Filing Date: February 8, 2000
Title: APPARATUS FOR DETERMINING WHEN A PATIENT IS
SUSCEPTIBLE TO DEFIBRILLATION


Dear Sir:

Enclosed for filing, pursuant to U.S.C. 371, in connection with the above-identified international patent application are the following:

1. Petition for Revival of an International Application for Patent Designating the U.S. Abandoned Unintentionally Under 37 C.F.R. 1.137(b);
2. Copy of the International Application;
3. Preliminary Amendment to be entered prior to calculating claim fees;
4. International Search Report (EPA) including copies of references cited therein;
5. International Preliminary Examination Report;
6. Check No. 215950 in the amount of \$1,248.00 (S/E 1.17(m) petition fee: \$620, S/E national fee with EPO search report: \$430, S/E extra claims fee: 7 x \$9 = \$63, S/E multiple dependent claim fee: \$135);
7. Deposit Account Authorization (in duplicate); and
8. Certificate of filing by Express Mail.

The applicant claims small entity status. Also enclosed is a postcard receipt which we ask that you acknowledge and return to us.

Respectfully submitted,



Richard M. Mescher
Reg. No. 38,242

Enclosures

Cincinnati • Cleveland • Columbus • Dayton • Naples, FL • Washington, DC
www.porterwright.com

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Inventors James Allen and Johnny Anderson

Title: "APPARATUS FOR DETERMINING WHEN A PATIENT IS
SUSCEPTABLE TO DEFRIBRILLATION"

Int. Applic. No. PCT/IB00/00205

U.S. Serial No.: tbd

U.S. Filing Date: tbd

PRELIMINARY AMENDMENT

Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

Please amend the above-identified application in the following manner prior to the examination thereof.

IN THE CLAIMS:

Please amend claims 6 and 7 in the following manner:

6. (amended) A defibrillator as claimed in claim 4, wherein the defibrillation voltage is an n-phasic truncated exponential voltage where n is greater than one.

7. (amended) A defibrillator as claimed in claim 4, wherein the defibrillation voltage is a biphasic truncated exponential voltage.

Please add new claims 8-11 in the following manner:

8. (new) A defibrillator as claimed in claim 5, wherein the defibrillation voltage is an n-phasic truncated exponential voltage where n is greater than one.

9. (new) A defibrillator as claimed in claim 5, wherein the defibrillation voltage is a

1870 1871 1872 1873 1874 1875 1876 1877 1878 1879 1880 1881 1882 1883 1884 1885 1886 1887 1888 1889 1890 1891 1892 1893 1894 1895 1896 1897 1898 1899 1900 1901 1902 1903 1904 1905 1906 1907 1908 1909 1910 1911 1912 1913 1914 1915 1916 1917 1918 1919 1920 1921 1922 1923 1924 1925 1926 1927 1928 1929 1930 1931 1932 1933 1934 1935 1936 1937 1938 1939 1940 1941 1942 1943 1944 1945 1946 1947 1948 1949 1950 1951 1952 1953 1954 1955 1956 1957 1958 1959 1960 1961 1962 1963 1964 1965 1966 1967 1968 1969 1970 1971 1972 1973 1974 1975 1976 1977 1978 1979 1980 1981 1982 1983 1984 1985 1986 1987 1988 1989 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 2034 2035 2036 2037 2038 2039 2040 2041 2042 2043 2044 2045 2046 2047 2048 2049 2050 2051 2052 2053 2054 2055 2056 2057 2058 2059 2060 2061 2062 2063 2064 2065 2066 2067 2068 2069 2070 2071 2072 2073 2074 2075 2076 2077 2078 2079 2080 2081 2082 2083 2084 2085 2086 2087 2088 2089 2090 2091 2092 2093 2094 2095 2096 2097 2098 2099 2100 2101 2102 2103 2104 2105 2106 2107 2108 2109 2110 2111 2112 2113 2114 2115 2116 2117 2118 2119 2120 2121 2122 2123 2124 2125 2126 2127 2128 2129 2130 2131 2132 2133 2134 2135 2136 2137 2138 2139 2140 2141 2142 2143 2144 2145 2146 2147 2148 2149 2150 2151 2152 2153 2154 2155 2156 2157 2158 2159 2160 2161 2162 2163 2164 2165 2166 2167 2168 2169 2170 2171 2172 2173 2174 2175 2176 2177 2178 2179 2180 2181 2182 2183 2184 2185 2186 2187 2188 2189 2190 2191 2192 2193 2194 2195 2196 2197 2198 2199 2200 2201 2202 2203 2204 2205 2206 2207 2208 2209 2210 2211 2212 2213 2214 2215 2216 2217 2218 2219 2220 2221 2222 2223 2224 2225 2226 2227 2228 2229 2230 2231 2232 2233 2234 2235 2236 2237 2238 2239 2240 2241 2242 2243 2244 2245 2246 2247 2248 2249 2250 2251 2252 2253 2254 2255 2256 2257 2258 2259 2260 2261 2262 2263 2264 2265 2266 2267 2268 2269 2270 2271 2272 2273 2274 2275 2276 2277 2278 2279 2280 2281 2282 2283 2284 2285 2286 2287 2288 2289 2290 2291 2292 2293 2294 2295 2296 2297 2298 2299 2300 2301 2302 2303 2304 2305 2306 2307 2308 2309 2310 2311 2312 2313 2314 2315 2316 2317 2318 2319 2320 2321 2322 2323 2324 2325 2326 2327 2328 2329 2330 2331 2332 2333 2334 2335 2336 2337 2338 2339 2340 2341 2342 2343 2344 2345 2346 2347 2348 2349 2350 2351 2352 2353 2354 2355 2356 2357 2358 2359 2360 2361 2362 2363 2364 2365 2366 2367 2368 2369 2370 2371 2372 2373 2374 2375 2376 2377 2378 2379 2380 2381 2382 2383 2384 2385 2386 2387 2388 2389 2390 2391 2392 2393 2394 2395 2396 2397 2398 2399 2400 2401 2402 2403 2404 2405 2406 2407 2408 2409 2410 2411 2412 2413 2414 2415 2416 2417 2418 2419 2420 2421 2422 2423 2424 2425 2426 2427 2428 2429 2430 2431 2432 2433 2434 2435 2436 2437 2438 2439 2440 2441 2442 2443 2444 2445 2446 2447 2448 2449 2450 2451 2452 2453 2454 2455 2456 2457 2458 2459 2460 2461 2462 2463 2464 2465 2466 2467 2468 2469 2470 2471 2472 2473 2474 2475 2476 2477 2478 2479 2480 2481 2482 2483 2484 2485 2486 2487 2488 2489 2490 2491 2492 2493 2494 2495 2496 2497 2498 2499 2500 2501 2502 2503 2504 2505 2506 2507 2508 2509 2510 2511 2512 2513 2514 2515 2516 2517 2518 2519 2520 2521 2522 2523 2524 2525 2526 2527 2528 2529 2530 2531 2532 2533 2534 2535 2536 2537 2538 2539 2540 2541 2542 2543 2544 2545 2546 2547 2548 2549 2550 2551 2552 2553 2554 2555 2556 2557 2558 2559 2560 2561 2562 2563 2564 2565 2566 2567 2568 2569 2570 2571 2572 2573 2574 2575 2576 2577 2578 2579 2580 2581 2582 2583 2584 2585 2586 2587 2588 2589 2590 2591 2592 2593 2594 2595 2596 2597 2598 2599 2600 2601 2602 2603 2604 2605 2606 2607 2608 2609 2610 2611 2612 2613 2614 2615 2616 2617 2618 2619 2620 2621 2622 2623 2624 2625 2626 2627 2628 2629 2630 2631 2632 2633 2634 2635 2636 2637 2638 2639 2640 2641 2642 2643 2644 2645 2646 2647 2648 2649 2650 2651 2652 2653 2654 2655 2656 2657 2658 2659 2660 2661 2662 2663 2664 2665 2666 2667 2668 2669 2670 2671 2672 2673 2674 2675 2676 2677 2678 2679 2680 2681 2682 2683 2684 2685 2686 2687 2

11. (new) A defibrillator as claimed in claim 8, wherein the defibrillation voltage is a biphasic truncated exponential voltage.

REMARKS

Claims 6 and 7 have been amended to remove multiple multiple-dependencies and new claims 8 to 11 have been added to incorporate the matter deleted from claims 6 and 7. Accordingly, claims 1 to 11 are currently pending in this application.

Enclosed herewith is a document containing marked-up versions of the changes made to the specification and claims by the current amendment. The document is captioned “**VERSION WITH MARKINGS TO SHOW CHANGES MADE**”.

In light of the foregoing, it is respectfully submitted that the present application is in a condition for allowance and notice to that effect is hereby requested. If it is found that that the present amendment does not place the application in a condition for allowance, applicant's undersigned attorney requests that the examiner initiate a telephone interview to expedite prosecution of the application.

If there are any fees resulting from this communication, please charge same to our Deposit Account No. 16-2326.

Respectfully submitted,

PORTER, WRIGHT, MORRIS & ARTHUR LLP

Robert M. Masley

Richard M. Mescher, Reg. No. 38,242

Porter, Wright, Morris & Arthur
41 South High Street
Columbus, OH 43215-6194
(614) 227-2026

September 6, 2001

VERSION WITH MARKINGS TO SHOW CHANGES MADE

IN THE CLAIMS:

The Preliminary Amendment makes the following changes:

6. (amended) A defibrillator as claimed in claim 4 [or 5], wherein the defibrillation voltage is an n-phasic truncated exponential voltage where n is greater than one.

7. (amended) A defibrillator as claimed in claim 4, [5 or 6,] wherein the defibrillation voltage is a biphasic truncated exponential voltage.

8. (new) A defibrillator as claimed in claim 5, wherein the defibrillation voltage is an n-phasic truncated exponential voltage where n is greater than one.

9. (new) A defibrillator as claimed in claim 5, wherein the defibrillation voltage is a biphasic truncated exponential voltage.

10. (new) A defibrillator as claimed in claim 6, wherein the defibrillation voltage is a biphasic truncated exponential voltage.

11. (new) A defibrillator as claimed in claim 8, wherein the defibrillation voltage is a biphasic truncated exponential voltage.

0936001-022002

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

APPARATUS FOR DETERMINING WHEN A PATIENT IS SUSCEPTIBLE
TO DEFIBRILLATION

This invention relates to an apparatus for determining
5 when a patient is susceptible to defibrillation.

Ventricular fibrillation (VF) is an abnormal rhythm of
the heart which proves fatal if left untreated. The
only effective treatment in an emergency situation is a
10 high voltage shock applied to the heart either through
electrodes applied to the chest wall or through
electrodes attached directly onto the heart's surface.
This high voltage shock attempts to interrupt the
Ventricular fibrillation sequence and thereby restore
15 the heart to a normal activation sequence.

A heart in VF is not effective and circulates very
little blood, if any at all. A VF event is therefore
probably the most time critical of all medical cases.
20 With no blood circulation, brain tissue death or
necrosis is imminent within minutes of the event
occurring. The lack of blood supply to the body also
compounds the time critical nature of the event because
the heart itself requires blood supply via its coronary
25 arteries in order to function efficiently. During VF
with the blood supply to the whole body interrupted,
the heart begins to experience ischaemia. Ischaemic
heart tissue is more prone to VF than normal heart
tissue. This means that as the VF rhythm persists, the
30 ability to correct the sequence reduces and the risk of
death increases.

There are various different mechanisms by which the

09/936001-022003

Ventricular fibrillation sequence can maintain itself. Unlike Normal Sinus rhythm (a one shot sequence being actively initiated by the Sino-atrial Node), VF is a self sustaining closed loop sequence which is sometimes cyclic in nature but the nature of the sequence and its mechanism invariably changes over time. Furthermore, the mechanism by which any particular VF event is sustained will be related to the primary cause of the event. There are again various cardiac related abnormalities and trauma, which can promote a VF sequence in any human heart. These can be divided into two distinct groups, namely: Primary VF events and Secondary VF events.

Primary events are cases where the VF was an unexpected event. This can either be a sudden spontaneously initiated VF or a VF event due to some other sudden trauma or stress e.g. Acute Myocardial Infarction, Hypoxia, Lightning strike etc. Secondary events are those which occur although suddenly but predictably. These would include VF as a known risk of drug therapy and also patients who have a previous history of spontaneous VF events or rhythms which could promote VF. These two groups are managed differently by modern clinical response.

Secondary events are very well controlled by complex and miniaturised Implantable Cardiac Defibrillators (ICDs) which are surgically implanted within the chest and have electrodes directly connected to the heart. These devices continually monitor the hearts rhythm and deliver a shock to the heart if they detect the abnormal rhythm. Devices such as these have a very high

success rate for converting VF since they can respond very quickly.

Primary events however are not so easily controlled.

- 5 Due to the fact that by nature they are entirely unpredictable, they invariably occur outside hospital and therefore occur in the absence of specialised equipment and or qualified personnel. When they do occur, the response time may be long because an average
- 10 person will fail to recognise the seriousness of the condition. This means that the event can neither be quickly diagnosed nor effectively treated. The advent of the Portable Cardiac Defibrillator was a significant advance for emergency response teams allowing them
- 15 access to a very specialised medical instrument outside hospital. The procedure means that primary events can now be treated almost as successfully as secondary events provided the emergency response team can be despatched and reach the patient in time. This delay
- 20 could be further reduced if the use of Automatic External Defibrillators (AED's) becomes more widespread.

- Unfortunately, there is a dilemma associated with
- 25 external defibrillation. Unlike ICDs, external defibrillators apply the electrical shock across the thorax rather than directly across the heart, requiring much larger voltages in order to deliver the energy to the heart, necessary for termination of the VF rhythm.
- 30 As a result of this high voltage, very high currents can occur within the thoracic cage and cause significant damage to heart tissue. Clearly this is

10

20

30

Although these types of refinement have advantages they do not increase the probability of defibrillation

success and they can also have serious disadvantages. For example while decreasing the width of a shock pulse and keeping the initial discharge voltage constant for a low impedance patient means the subject receives a lower energy dose, the initial current flow through the subjects torso (and heart) is actually much greater and therefore very damaging.

Present theory projects that the state of the myocardium at the exact instant the shock is applied is actually the determining factor of a successful defibrillation attempt. Experiments changing the shape of the shock pulse itself have shown that different pulse shape characteristics can change the amount of energy required to terminate VF. It is widely accepted that although VF has a random appearance, it is characteristic and can in fact be successfully modelled.

Investigations in this field have shown that the success of a defibrillation attempt is governed by the ability of the applied shock pulse and its shape to successfully organise a critical mass of myocardial cells. Specifically, the critical mass of cells must be placed into the refractory (or recovery) state. If a critical mass can be organised in this way, the heart essentially pauses. The normal sinus pacemaker can then initiate the heart's normal activation sequence and normality is restored.

Recently however, investigators have shown that during VF the heart's organisational state changes over time, and specifically that there are instants during any VF

- sequence at which the heart is in a more organisational state. Attempts by various investigators to identify these instants (called periods or instants of defibrillation susceptibility) have only been
- 5 marginally successful. In 1988 Carlisle et al. synchronised the applied shock to the peaks, troughs and zero crossing points of the ECG during VF, without any significant success.
- 10 The object of the invention is therefore to provide a means for determining when a patient is susceptible to defibrillation whereby the probability of any defibrillation attempt being successful can be increased.
- 15 Accordingly, the invention provides an apparatus for determining when a patient is susceptible to defibrillation, the system comprising a plurality of electrodes for obtaining an electrocardiographic (ECG)
- 20 signal from a patient, and data processing means for (a) determining a region of the ECG signal where such signal passes from a first threshold to a second threshold at least equal in magnitude to that of the first threshold and of opposite polarity thereto while
- 25 the gradient of such signal remains within certain limits, (b) detecting the next following ECG signal peak, and (c) providing an output signal upon such detection.
- 30 The invention further provides defibrillation apparatus in which the occurrence of the output signal is used to trigger the application of a defibrillation voltage across the defibrillation electrodes.

00000001-020000

In such case the electrodes providing the ECG signal may be the defibrillation electrodes themselves.

- 5 The first and second thresholds and gradient limits may be calculated automatically from measured parameters of the preceding ECG signal, or they may be empirically determined constant values.
- 10 In the embodiment to be described the data processing means is implemented in digital circuitry. However, it may alternatively be implemented in analog circuitry or a combination of analog and digital circuitry.
- 15 An embodiment of the invention will now be described, by way of example, with reference to the accompanying drawings, in which:
- Fig. 1 shows a single bipolar lead ECG showing a normal
20 sinus beat measured from the body surface,
- Fig. 2 is a diagram of a heart showing average cardiac vectors at four instants during a normal sinus beat corresponding to the ECG in Fig. 1,
- 25 Fig. 3 shows normal sinus rhythm,
- Fig. 4 shows normal depolarisation and repolarisation of an isolated section of myocardium,
- 30 Fig. 5 is a typical bipolar ECG trace showing VF,
- Fig. 6 shows a possible activation mechanism generating

a VF ECG trace,

Fig. 7 shows a single re-entrant activation loop,

5 Fig. 8 shows the VF epoch of Fig. 5 with time markers showing the defibrillation points identified by the prior art,

Fig. 9 illustrates the detection constraints imposed
10 by the invention,

Fig. 10 shows the VF epoch of Fig. 5 with time markers showing the points identified by the invention,

15 Fig. 11 shows defibrillation apparatus embodying the invention,

Fig. 12 is a functional block diagram of the internal circuitry of the apparatus of Fig. 11,
20

Fig. 13 is a flow diagram of the operation of the shock point detector of Fig. 12,

Fig. 14 is an example of the use of the invention to
25 terminate a VF sequence through delivery of a biphasic electrical shock, and

Fig. 15 is an example of the use of the invention terminating multiple re-entrant loops to form a
30 dominant re-entrant loop.

The invention is based on the theory that the instants of susceptibility can be detected and quantified by the

average cardiac vector but that the amplitude and velocity of the approaching dominant wavefront is insufficient to accurately determine the instant of susceptibility. The instantaneous direction of the dominant wavefront and the nature of the myocardial organisation responsible for this direction is crucial to identifying the exact instant of susceptibility.

Fig. 1 shows an ECG obtained from a heart in normal sinus rhythm. Fig. 2 shows a diagrammatic sketch of the heart with the average cardiac depolarisation vectors superimposed. Each vector is called an average vector because it depicts the sum of all the myocardial cells activated at that particular point in time. The vectors are numerically labelled to portray the time sequence and can be related to the ECG trace Fig. 1 in order to appreciate the myocardial organisation at any given time instant. Note that the placement of the electrodes e1 and e2 shown in Fig. 2 (which in this case are the defibrillation electrodes ultimately used to shock the heart) determines the shape of the acquired ECG so the organisational state of the heart at any given time instant as determined by any given ECG lead is with reference to the direction resolved by that particular lead. Note also that normal Sinus rhythm is a very stable sequence repeated in a controlled manner by the heart, Fig. 3 shows an example ECG lead trace for reference.

Further considering Fig. 1, it can be appreciated that as the heart activates the average cardiac vector changes position from that denoted by t_1 to t_2 then to t_3 and finally to t_4 . Of particular interest here is

that the ECG traces achieves maximum positive deflection between time instants t_2 and t_3 . Referring now to Fig. 2 we see that between t_2 and t_3 the vector would be pointing in the direction of the axis between the two electrodes e_1 and e_2 . It is a fundamental property of any bipolar ECG lead that when a depolarising myocardial wavefront is approaching along the axis of the lead, a maximum (positive) deflection will be measured and when it is retreating along the axis of the lead, a minimum (negative) deflection will be measured. Furthermore, if the wavefront is travelling in a direction perpendicular to the lead axis, no deflection (zero potential difference) will be measured. Before considering the properties of a VF sequence it must be appreciated that the ECG trace and the average cardiac vectors are a consequence of the activation wavefronts.

Fig. 4 shows how the activation of an isolated section of myocardium can be used to demonstrate a normal depolarisation and repolarisation sequence. Note that the average vectors are differentiated by a "- sign" for the depolarisation wave and a "+ sign" for the repolarisation wave. Above the tissue section we can also see the electrical trace which this isolated activation would produce measured from the two electrodes positioned either side of the section. The measured ECG trace shows the sharper, faster depolarisation wave inscribing a positive deflection as it approaches the positive electrode, this is then followed by the slower repolarisation wave which inscribes a negative deflection. The repolarisation wave is negative because it is of the opposite polarity

(positive rather than negative) as it approaches the positive electrode.

- This particular activation sequence (with the repolarisation wave following behind the initial depolarisation wave) is typical of atrial tissue. Ventricular tissue actually repolarises in the opposite direction to which it initially depolarises. In terms of the measured ECG and Fig. 4 the only difference would be that for ventricular tissue, since the repolarisation wave would be receding away from the positive electrode it would actually inscribe a positive deflection in the ECG trace.
- Now let us consider a VF trace and how myocardial tissue generates such a trace. Fig. 5 shows a typical epoch of VF. As we can see the trace does indeed appear random. This sequence is generated by tissue containing a varying number of wavefronts. Fig. 6 shows one possibility. Here we see that there are several wavefronts circulating without any apparent stimulus. These "loops" are self sustaining because the tissue is repolarising abnormally quickly so that the depolarising wavefront can actually reactivate the tissue rather than allowing the tissue to pause and wait for a normal stimulus. Note that since the individual wavefronts are completely independent, they will interfere so that the overall activation vector changes with time as presented by the ECG trace.
- Furthermore, in this particular example the "loops" are all the same diameter, this however would not necessarily be the case. It must now be appreciated

that at any given time instant the wavefronts can be seen to be adding together more than at other times, resulting in a higher amplitude activation vector being measured externally. At other times the wavefronts
5 could interfere more destructively causing lower amplitude activation vectors to be measured.

Fig. 7 shows another possibility. Here only one large wavefront is shown circulating around the entire tissue
10 section. The nature of this particular tissue activation pattern is the most fundamental type of self-sustaining "or re-entrant" activation. This more basic type of abnormal activation is more descriptive of a Ventricular Tachycardia sequence. Note that as
15 this single wavefront rotates, at any time instant there are large areas of the tissue section which be can be noted as either depolarised or repolarised. In fact at any time instant there will be almost one half of the tissue section depolarised and one half
20 repolarised. If we now deliver an electric shock at a random time instant to the tissue section, it is clear why such a shock may only sometimes be successful. At the instant the shock is applied, the areas of tissue that are depolarised will be unaffected, the areas that
25 are repolarised (and therefore ready for activation) will begin to depolarise. Since these areas are depolarised earlier as a result of the shock stimulus, they cannot now be activated again by the already present circulating wavefront. The activation sequence
30 is therefore terminated by interruption of the re-entrant loop. Note therefore that to successfully terminate such an abnormal sequence, the electrical

0936001-02200

shock should be delivered at any time instant where the result of the shock would be to cause a significant amount of the tissue mass to be depolarised so as to interrupt the abnormal sequence. This implies that the electrical shock should be applied at any time instant where there is a significant amount of the tissue mass in a state of repolarisation.

If we now return to Fig. 6 and consider again how these individually circulating wavefronts interfere with each other over time, then we can see that the average cardiac vector and it's measurement (the ECG trace) is generated by the activation wavefronts combined. Note also that the act of measuring a threshold or a gradient at that threshold is not sufficient to determine the activation state of the tissue. Since the amplitude of the ECG trace is due to both the mass of tissue activation together with the direction in which it is activating they cannot be separated by a threshold. Furthermore the gradient only reveals the speed at which the overall wavefront is approaching or receding.

Fig. 8 shows time instant markers positioned at points along the trace of Fig. 5 where the prior art suggests susceptibility for defibrillation. It is the purpose of this invention to identify the optimum instant for susceptibility for interruption of a re-entrant loop by using the ECG trace to determine both from which direction the overall wavefront is coming and also in which direction it is going. This is achieved by noting a peak average cardiac vector of significant amplitude

and then detecting an amplitude of like magnitude but of opposite polarity immediately following the first noted peak. Furthermore the form of the ECG trace between these instants of opposite polarity must be appreciably linear (that is to say of relatively uniform gradient). The average cardiac vector presents this property when the overall activation is due to a significantly sized activation wavefront travelling away from a point far from the positive sensing electrode to a point near to the same electrode. Upon detection of a wavefront with this property at the positive electrode, there will be a significant mass of tissue having just been depolarised and therefore emerging from recovery ready for activation. Note also that this tissue mass will have been travelling in a direction towards the positive electrode, meaning that the intracellular current flow within the tissue will also be directed in that direction. The defibrillating shock should therefore be delivered immediately upon detection of this instant so that the sequence can be successfully interrupted.

Furthermore it is crucial that the polarity of the defibrillation shock is such that the critical mass of cells are depolarised and that the shock is not applied across the tissue in a direction attempting to reverse repolarisation. A reverse polarity shock would require more energy since it would have to both reverse repolarisation and then depolarise the critical mass, a process which is very unlikely since having attempted to reverse repolarisation, the critical mass of cells will be less likely to depolarise properly and the VF

sequence would simply persist.

Thus, as shown in Fig. 9 for a negative-to-positive-going portion of the ECG signal, the object of the invention is to identify a region of the ECG signal where the signal passes from a negative threshold "-th" of significant magnitude to a positive threshold "+th" at least equal in magnitude to the negative threshold, while the gradient of the signal remains within certain limits. In Fig.9, provided the signal stays within the "channel" defined by the notional inclined parallel dotted lines separated by the horizontal distance $\delta\alpha$, it is assumed that the gradient has remained within the required limits. Having detected such a region of the ECG signal, the optimum point for defibrillation is at the next following ECG signal peak, i.e. local maximum, at which the defibrillation shock should be delivered.

The invention is equally applicable to positive-to-negative-going portions of the ECG signal, in which case one would detect a region of the ECG signal where the signal passes from a positive threshold of significant magnitude to a negative threshold at least equal in magnitude to the positive threshold, while the gradient of the signal remains within certain limits, and the optimum point for defibrillation would be at the next following local minimum of the ECG signal.

Fig. 10 shows the previous epoch of VF from Fig. 5 but here the above technique has identified only the instants $tn1$ and $tn2$ which were truly susceptible to defibrillation. As mentioned previously, the upper and lower thresholds, indicated in Fig. 10 by the

horizontal dashed lines, and the gradient limits may be calculated automatically from measured parameters of the preceding ECG signal, or they may be empirically determined constant values. In the case of Fig. 10 the
5 thresholds are assumed to be a function of the average peak value of the preceding ECG signal.

An embodiment of the invention is shown in Figs. 11 to 13 and is based upon a known type of external
10 defibrillation apparatus. Since the modifications necessary to embody the invention are internal, the apparatus has the outward appearance (Fig. 11) of a conventional external defibrillation apparatus.

15 Thus the apparatus includes a defibrillation unit 10 and a pair of defibrillation electrodes 12, 14 for application to a human torso 16, the electrodes being plugged into the unit 10. As well as being used to provide a defibrillation shock, the electrodes 12, 14
20 are also used as ECG electrodes to produce an ECG signal in known manner which is displayed on an ECG monitor 18 in the unit 10. A gain control knob 20 allows the amplitude of the signal trace to be adjusted on the monitor 18. The unit 16 also includes a rotary
25 dial 22 to select the energy of the defibrillation shock to be applied to the patient, and a push button 24 which when pressed causes a capacitor inside the unit 16 to charge to a voltage determined by the setting of the selector 22. Finally, a further push
30 button 26 is provided. In the conventional defibrillator an operator pushes this button to cause the capacitor to discharge through the electrodes 10, 12 to deliver a shock to the patient. However, in the

present case the internal circuitry of the unit 16 is modified so that pushing the button 26 merely enables a shock to be given, the actual timing of the shock being determined according to the principles discussed above
5 with reference to Fig. 9.

Fig. 12 is a block diagram of internal circuitry of the unit 10. The individual blocks shown in Fig. 12 identify the main functions of the unit, and do not
10 necessarily constitute separate and distinct parts of the circuitry.

Signal Conditioning and Amplification circuit 30 receives the signals from the individual defibrillation
15 electrodes 12, 14 and generates therefrom in known manner the ECG signal for display on the monitor 18. Energy Select circuit 32 is responsive to the setting of the rotary dial 22 to establish the selected energy level and, when the push button 24 is pressed, Charge
20 circuit 34 charges the capacitor to a level corresponding to the selected energy level.

In the prior art, and as indicated by the dashed line, Shock Enable circuit 36 is directly responsive to the
25 operator pressing the push button 26 to provide an input to Shock Delivery circuit 38, causing the latter to immediately discharge the capacitor through the electrodes 12, 14 to deliver a defibrillation shock to the patient. However, in the present embodiment the
30 Shock Enable circuit 36 provides instead an input to Trigger Shock circuit 40 interposed between circuits 36 and 38. The Trigger Shock circuit 40 also receives an input from Shock Point Detector circuit 42 which is

responsive to the ECG signal from circuit 30 to detect
instants susceptible to defibrillation according to the
principles of Fig. 9. The Shock Point Detector circuit
42 provides the said input to circuit 40 when such an
5 instant is detected.

The Trigger Shock circuit 40 is essentially an AND
circuit and, when it receives an input simultaneously
from both circuits 36 and 42, it provides an input to
10 the Shock Delivery Circuit 38 which causes the latter
to immediately discharge the capacitor through the
electrodes 12, 14 to deliver a defibrillation shock to
the patient. Thus, as compared to the conventional
external defibrillator which provides a defibrillation
15 shock immediately the button 26 is pressed, which can
occur at any arbitrary point during the ECG cycle due
to the rapid changes in the signal and the relatively
slow reaction of the human operator, in the present
apparatus when the button 26 is pressed the apparatus
20 waits until the Shock Point Detector circuit 42
identifies an instant susceptible to defibrillation and
only then administers the shock. Such instant will
typically occur a fraction of a second after the button
26 is pressed, and thus the button 26 must be held down
25 until the shock is given. Optionally, if no suitable
instant is detected within a predetermined time, say
about two seconds, after the button 26 is pressed, the
apparatus may be designed to administer a shock at that
point anyway. The shock is preferably an n-phasic
30 truncated exponential shock where n is greater than
one. That is to say, it consists of several truncated
exponential voltage pulses of alternating polarity. In
particular it may be a biphasic truncated exponential

shock.

The implementation of circuits 30 to 38 is well known in the art and does not need further description.

5 Also, circuit 40 is essentially an AND circuit and is readily implemented by those skilled in the art. The function of the Shock Point Detector circuit 42 is performed in this embodiment by a suitably programmed microprocessor. In order to allow the microprocessor
10 to process the ECG signal an analog-to-digital (A/D) converter (not shown) is used to convert the analog ECG signal to digital form.

Fig. 13 is a flow diagram of the program which is run
15 on the microprocessor to identify the instants susceptible to defibrillation. The program starts when the push button 26 is pressed. Step 50 repeatedly tests the ECG signal to detect the ECG signal crossing a predetermined negative threshold in a positive-going
20 direction, and when such a crossing is detected step 52 analyses the signal to determine its instantaneous gradient. Step 54 tests the gradient thus determined for being within predetermined limits. If the gradient is not within the limits, control passes back to step
25 50. If it is within limits, step 56 tests to determine if the signal has crossed a predetermined positive threshold at least equal in magnitude to that of the negative threshold. If it has, step 58 detects the next following peak (local maximum) and step 60
30 provides an output to the Trigger Shock circuit 40. If, however, step 56 determines that the signal has not crossed the positive threshold, control returns to step 52 and steps 52 to 56 are run through again. Thus, as

time progresses from the crossing detection at step 50 the program repeatedly tests the gradient for being within limits, until either the signal crosses the positive threshold, in which case the next following peak is detected, or the gradient falls outside the limits, in which case control reverts to step 50 to look for the next crossing of the negative threshold.

Fig. 14 shows the invention having identified the correct instant of susceptibility and a biphasic truncated exponential shock was delivered to successfully terminate the VF event. The invention can also be used to terminate VF sequences sustained by multiple re-entrant loops as described above and shown in Fig. 6. In this instance the invention identifies the instant of greatest susceptibility and a first shock is delivered. Fig. 15 shows this process. As the figure shows, the purpose of the first shock is not to activate a critical mass and thereby terminate the VF sequence, but rather to just merge some of the small loops into one bigger loop. Successive shocks can therefore merge the loops into bigger and bigger loops until a final shock terminates the VF sequence.

The invention has been used to identify the instant of susceptibility in each case. This means that the energy required to defibrillate (either single shock or through multiple sequential shocks) is considerably less than would be required to activate a critical mass at a time instant that is not susceptible.

Although the above embodiment has used the same electrodes for both defibrillation and to provide the

ECG signal which is analysed to determine the instant of susceptibility to defibrillation, the ECG signal could alternatively be derived from separate electrodes.

5

Also, although the foregoing has described the invention in the context of an external defibrillator, i.e. where the electrodes are connected externally to the patient's body, it will be clear to those skilled in the art that the invention may be used to determine the instant of susceptibility to defibrillation in the case of implanted electrodes which are connected directly to the heart's surface.

10

15 The invention is not limited to the embodiments described herein which may be modified or varied without departing from the scope of the invention.

09936004 022003

CLAIMS

1. An apparatus for determining when a patient is susceptible to defibrillation, the system comprising a plurality of electrodes for obtaining an electrocardiographic (ECG) signal from a patient, and data processing means for (a) determining a region of the ECG signal where such signal passes from a first threshold to a second threshold at least equal in magnitude to that of the first threshold and of opposite polarity thereto while the gradient of such signal remains within certain limits, (b) detecting the next following ECG signal peak, and (c) providing an output signal upon such detection.
2. An apparatus as claimed in claim 1, wherein the first threshold is a negative threshold and the second threshold is a positive threshold.
3. An apparatus as claimed in claim 1, wherein the first threshold is a positive threshold and the second threshold is a negative threshold.
4. A defibrillator including an apparatus as claimed in claim 1, 2 or 3 wherein the occurrence of the output signal is used to trigger the application of a defibrillation voltage across defibrillation electrodes.
5. A defibrillator as claimed in claim 4, wherein the electrodes providing the ECG signal are also the defibrillation electrodes.

6. A defibrillator as claimed in claim 4 or 5, wherein the defibrillation voltage is an n-phasic truncated exponential voltage where n is greater than one.

5

7. A defibrillator as claimed in claim 4, 5 or 6, wherein the defibrillation voltage is a biphasic truncated exponential voltage.




Fig.1




Fig.2

200220* 1009E660

3/15




Fig.3




Fig.4




Fig. 5




Fig.6

09/936001 PCT/IB00/00205




Fig.7

200220" 1009660

200220" T009E660




Fig.8




Fig.9

10/15






Fig.10

FIG. 11



12/15

Fig 12






FIG.13.




Fig.14




Fig.15

09/936001 0200

DECLARATION AND POWER OF ATTORNEY

As a below named inventor, I hereby declare that: My citizenship, residency, and mailing address are as identified below next to my name. I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed therein and for which a patent is sought on the invention entitled

"APPARATUS FOR DETERMINING WHEN A PATIENT IS SUSCEPTIBLE TO DEFIBRILLATION";

the specification of which was filed on 02/08/2000 (MM/DD/YYYY) as PCT International Application Number PCT/IB00/00205 and was amended by Preliminary Amendment filed to the USPTO on 09/06/01 (MM/DD/YYYY).

I hereby state that I have reviewed and understand the content of the above-identified specification, including the claims, as amended by any amendment specifically referred to above.

I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR 1.56.

I hereby claim foreign priority benefits under 35 U.S.C. 119(a)-(d), or 365(b) of any foreign application(s) for patent or inventor's certificate(s), or 365(a) of any PCT international application(s) which designated at least one country other than the United States of America, listed below and have also identified below, any foreign application(s) for patent or inventor's certificate(s), or any PCT international application(s) having a filing date before that of the application on which priority is claimed.

<u>Country</u>	<u>Prior Foreign Application No.</u>	<u>Foreign Filing Date (MM/DD/YYYY)</u>	<u>Priority Claimed?</u>	<u>Certified Copy Attached?</u>
Ireland	S990090	02/08/1999	Yes	No

I hereby designate the following as my mailing address:

Porter, Wright, Morris & Arthur LLP
ATTN: Intellectual Property Department
41 South High Street, 28th Floor
Columbus, Ohio 43215-6194

I hereby request that all telephone calls be directed to: Richard M. Mescher at (614) 227-2026

I hereby appoint each of the following as my attorneys, with full power of substitution and revocation, to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith:

Edwin M. Baranowski, Reg. No. 27,482;
Laurie N. Jacques, Reg. No. 35,905; and
Richard M. Mescher, Reg. No. 38,242.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made herein on information and belief are believed to be true, and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, Section 1001, and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

(1) Inventor: JAMES ALLEN
Citizenship: Great Britain
Inventor's Signature: [Signature]
Date Signed: 24th JAN 2002.
Residence: Muckamore, Great Britain
Mailing Address: 10 Dunadry Road
Muckamore, County Antrim
BT15 4SQ GREAT BRITAIN

SYCAMORE STABLES
55 BALLYMARTIN RD
TEMPLEPATRICK
BALLYCHARE CO ANTRIM
BT39 0BS GREAT BRITAIN.

GBX

(2) Inventor: JOHNNY HOUSTON ANDERSON
Citizenship: Great Britain
Inventor's Signature: J. Anderson
Date Signed: 24th JAN 2002.
Residence: Hollywood, Great Britain
Mailing Address: 16 Torgrange
Hollywood, County Down
BT18 0NG GREAT BRITAIN

58 ARDMORE ROAD
HOLLYWOOD
CO. DOWN
N. IRELAND IEY
BT18 0PJ